Voxilaprevir - Misplaced Pages

Protease inhibitor

Pharmaceutical compound

Voxilaprevir
Clinical data

Trade names	Vosevi (combination with sofosbuvir and velpatasvir)
Identifiers
IUPAC name (1R,18R,20R,24S,27S,28S)-N-carbamoyl}cyclopropyl]-28-ethyl-13,13-difluoro-7-methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclononacosa-3(12),4,6,8,10-pentaene-27-carboxamide
CAS Number	1535212-07-7
PubChem CID	89921642
ChemSpider	44209500
UNII	0570F37359
KEGG	D10899
PDB ligand	L9P (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID301027947
Chemical and physical data
Formula	C₄₀H₅₂F₄N₆O₉S
Molar mass	868.94 g·mol
3D model (JSmol)
Density	1.4±0.1 g/cm
SMILES CC12CN(1C(=O)N3(C3C(F)F)C(=O)NS(=O)(=O)C4(CC4)C)C(=O)(NC(=O)O5C5CCCCC(c6c(nc7cc(ccc7n6)OC)O2)(F)F)C(C)(C)C
InChI InChI=1S/C40H52F4N6O9S/c1-7-22-27-19-50(28(22)32(51)48-39(18-23(39)31(41)42)35(53)49-60(55,56)38(5)14-15-38)34(52)30(37(2,3)4)47-36(54)59-26-16-20(26)10-8-9-13-40(43,44)29-33(58-27)46-25-17-21(57-6)11-12-24(25)45-29/h11-12,17,20,22-23,26-28,30-31H,7-10,13-16,18-19H2,1-6H3,(H,47,54)(H,48,51)(H,49,53)/t20-,22-,23+,26-,27+,28+,30-,39-/m1/s1 Key:MZBLZLWXUBZHSL-FZNJKFJKSA-N

Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir. The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.

On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.

References

"voxilaprevir_msds".
Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556. S2CID 4395880.
"Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017. Archived from the original (PDF) on 18 June 2018. Retrieved 27 June 2017.
FDA approves Vosevi for Hepatitis C

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir Ciluprevir Danoprevir Faldaprevir Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir Sovaprevir Telaprevir Vaniprevir Vedroprevir Voxilaprevir
NS5A inhibitors (–asvir)	Coblopasvir Daclatasvir Elbasvir Ledipasvir Odalasvir Ombitasvir Pibrentasvir Ravidasvir Ruzasvir Samatasvir Velpatasvir
NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir Bemnifosbuvir Dasabuvir Deleobuvir Filibuvir GS-6620 IDX-184 Setrobuvir Sofosbuvir Tegobuvir TMC-647055 Radalbuvir Uprifosbuvir
Combination drugs	Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir Ombitasvir/paritaprevir/ritonavir Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir Sofosbuvir/velpatasvir/voxilaprevir

Anti-influenza agents

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a Peginterferon alfa-2b
3CL protease inhibitors (–trelvir)	Ensitrelvir Ibuzatrelvir Lufotrelvir Nirmatrelvir (+ritonavir) Rupintrivir Simnotrelvir (+ritonavir)
RNA pol inhibitors	CMX521 Deuremidevir Favipiravir Galidesivir GS-441524 Remdesivir MK-608 Mericitabine Molnupiravir NITD008 Ribavirin Taribavirin Triazavirin Valopicitabine
Multiple/Unknown/Other	EICAR Merimepodib Moroxydine Presatovir

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.